Vaccination with NH36 has proven to protect against murine cutaneous and visceral leishmaniasis (19–24) and canine visceral leishmaniasis (26, 27), through an IFN-γ-CD4 response (21, 24). Here, IFNG is linked to visceral leishmaniasis.